N-myristoylation is a common form of co-translational protein fatty acylation resulting from the attachment of myristate to a required N-terminal glycine residue 1, 2 . We show that aberrantly acquired N-myristoylation of SHOC2, a leucine-rich repeat-containing protein that positively modulates RAS-MAPK signal flow [3] [4] [5] [6] , underlies a clinically distinctive condition of the neuro-cardio-facial-cutaneous disorders family. Twenty-five subjects with a relatively consistent phenotype previously termed Noonan-like syndrome with loose anagen hair (MIM607721) 7 shared the 4A4G missense change in SHOC2 (producing an S2G amino acid substitution) that introduces an N-myristoylation site, resulting in aberrant targeting of SHOC2 to the plasma membrane and impaired translocation to the nucleus upon growth factor stimulation. Expression of SHOC2 S2G in vitro enhanced MAPK activation in a cell typespecific fashion. Induction of SHOC2 S2G in Caenorhabditis elegans engendered protruding vulva, a neomorphic phenotype previously associated with aberrant signaling. These results document the first example of an acquired N-terminal lipid modification of a protein causing human disease.
Dysregulation of the RAS-MAPK signaling pathway has recently been recognized as the molecular cause underlying a group of clinically related developmental disorders with features including reduced growth, facial dysmorphism, cardiac defects, ectodermal anomalies, variable cognitive deficits and susceptibility to certain malignancies 8, 9 . These mendelian traits are caused by mutations in genes encoding RAS proteins (KRAS and HRAS), downstream transducers (RAF1, BRAF, MEK1 and MEK2) or pathway regulators (PTPN11, SOS1, NF1 and SPRED1). For Noonan syndrome, the commonest of these disorders, mutations are observed in several of these genes, underlying approximately 70% of cases.
To rationalize further candidate gene approaches to Noonan syndrome gene discovery, we used a systems biology approach based on in silico protein network analysis. By applying a graph theory algorithm on a filtered consolidated human interactome, we derived a subnetwork of proteins generated from an integrated network of mammalian protein interaction databases and cell-signaling network datasets by seeding with the known disease-causing mutant proteins ( Supplementary Fig. 1a ). To identify potential Noonan syndrome disease genes, we computed Z scores using a binomial proportions test, which ranked the significance of the intermediate nodes within the subnetwork based on their connections to the seed proteins 10 (Supplementary Table 1 ). We resequenced coding exons for the best gene candidate, SHOC2, in a Noonan syndrome cohort that included 96 individuals who were negative for mutations in known disease genes and who were opportunely selected to represent the wide phenotypic spectrum characterizing Noonan syndrome; this revealed an A-to-G transition at position 4 of the gene, predicting the substitution of a glycine for serine at position 2 (S2G), in four unrelated individuals ( Supplementary Fig. 1b ). All cases were diagnosed as sporadic, and genotyping of parental DNA available for three of the four subjects documented the absence of the sequence variant and confirmed paternity in each family, providing evidence that the change was a de novo mutation associated with the disease. For these subjects, DNA samples from several tissues were available, and all harbored the S2G mutation, providing evidence that the defect was inherited through the germline. We then analyzed SHOC2 in a cohort of 410 mutation-negative subjects with Noonan syndrome or a related phenotype. We observed 21 individuals with the 4A4G missense change and proved that the causative mutations were de novo in 12 families from which parental DNA was available. No additional disease-associated SHOC2 sequence variant was identified in this cohort, strongly suggesting a specific pathogenetic role for the S2G amino acid substitution.
Review of the clinical features of individuals with the SHOC2 mutation revealed a consistent phenotype, previously termed Noonanlike syndrome with loose anagen hair 7 . Although their facial features seemed typical of Noonan syndrome (Fig. 1a) , phenotypic analysis of these subjects was notable in that they showed reduced growth that was frequently associated with proven growth hormone deficiency, cognitive deficits, distinctive hyperactive behavior that improved with age in most subjects, and hair anomalies including easily pluckable, sparse, thin, slow-growing hair. In 12 subjects, a diagnosis of loose anagen hair was confirmed by microscopic examination of pulled hairs. Most of the subjects also had darkly pigmented skin with eczema or ichthyosis. Cardiac anomalies were observed in the majority of the subjects, with dysplasia of the mitral valve and septal defects considerably overrepresented compared with the general population of individuals with Noonan syndrome. The affected individuals' voices were characteristically hypernasal. Of note, the referring pediatricians felt that several of these subjects had features suggestive of Costello syndrome or of cardiofaciocutaneous syndrome as newborns or young infants. Overall, these subjects appeared to share a phenotype that was characterized by an unusual combination of features observed in disorders of the neuro-cardio-facial-cutaneous disorders family (Supplementary Table 2 ).
SHOC2 is a widely expressed protein composed almost entirely of leucine-rich repeats (LRR), with a lysine-rich sequence at the N terminus (Fig. 1b) . In C. elegans, where SHOC2 (also called SUR-8 and SOC-2) was discovered, the SHOC2 protein acts as a positive modulator of the RAS-MAPK signaling cascade, which is elicited by EGL-15 and LET-23 and mediated by LET-60 (homologs of vertebrate FGFR, EGFR and RAS family members, respectively 3, 4 ). Because LRRs can provide a structural framework for protein-protein interactions, SHOC2 is believed to function as a scaffold, linking RAS to downstream signal transducers [4] [5] [6] . Based on the N-terminal position of the S2G substitution, we hypothesized that co-translational processing might be perturbed in the mutant protein, making it a substrate for N-myristoyltransferase (NMT). N-terminal myristoylation is an irreversible modification generally occurring during protein synthesis, in which myristate, a 14-carbon saturated fatty acid, is covalently added to an N-terminal glycine residue after excision of the initiator methionine residue by methionyl aminopeptidase 1, 2 . For this to occur, glycine at codon 2 is absolutely required, small uncharged residues at positions 3 and 6 are generally needed, and basic residues at positions 7-9 are preferred 11 . Except for the presence of serine at position 2, the N-terminal sequence of SHOC2 satisfies those consensus rules, and in silico analysis predicted myristoylation of the SHOC2 S2G mutant with high confidence. To verify this, we evaluated the myristoylation status of wild-type and mutant SHOC2 proteins transiently expressed in Cos-1 cells (Fig. 2a) . We found that SHOC2 S2G incorporated [ 3 H]myristic acid, whereas the wild-type protein and the diseaseunrelated SHOC2 S2A did not.
N-myristoylation facilitates the anchoring of proteins to cellular membranes. To explore whether this process conferred membrane targeting to mutant SHOC2, the subcellular localization of V5-tagged SHOC2 proteins was analyzed in Cos-1 cells (Fig. 2) . Confocal laser scanning microscopy analysis showed that SHOC2 wt was uniformly distributed in the cytoplasm and nucleus in starved cells, but that it was restricted to the nucleus following epidermal growth factor (EGF) stimulation, implying an unexpected role for this protein in signal transduction. In contrast, SHOC2 S2G was specifically targeted to the cell membrane both in starved cells and after EGF stimulation. This aberrant localization of SHOC2 S2G was confirmed in 293T and Neuro2A cell lines and using a Myc-tagged protein (data not shown) as well as by cell fractionation (Fig. 2c) . Growth factorstimulated nuclear translocation of the endogenous SHOC2 protein was confirmed in primary skin fibroblasts (Fig. 2e) . Treatment with 2-hydroxymyristic acid, an NMT inhibitor, at varying doses reduced or abolished the membrane localization of SHOC2 S2G ( Supplementary  Fig. 2 ), confirming a dependency upon myristoylation. In addition, Figure 1 The germline 4A4G mutation in the SHOC2 gene causes a distinctive phenotype of the neuro-cardio-facial-cutaneous syndrome family. (a) Representative phenotypic features of affected subjects carrying the SHOC2 mutation. Common features include macrocephaly, high forehead, hypertelorism, palpebral ptosis, low-set and posteriorly rotated ears, short and webbed neck, and pectus anomalies. Affected subjects also had easily pluckable, sparse, thin, slow-growing hair. (b) SHOC2 genomic organization and protein structure. The coding exons are shown at the top as numbered filled boxes. Intronic regions are represented by dotted lines. SHOC2's motifs comprise an N-terminal lysine-rich region (in gray; Prosite motif score ¼ 8.8) followed by 19 leucine-rich repeats (Pfam hits with an E value o0.5 are in black and those with an E value 41 in white). Numbers above the domain structure indicate the amino acid boundaries of those domains.
even in the absence of efficient myristoylation, SHOC2 S2G did not translocate to the nucleus upon stimulation, indicating possible loss of function. Efficient nuclear translocation was observed for the diseaseunrelated SHOC2 S2A mutant following EGF stimulation (Supplementary Fig. 3) , suggesting a specific effect of the mutation that causes disease. To exclude the possibility that SHOC2 S2G might exert a dominant negative effect by sequestering the wild-type protein to the cell membrane, thereby impairing its EGF-dependent translocation to the nucleus, we assayed SHOC2 wt and SHOC2 S2G heterodimerization by confocal microscopy and coimmunoprecipitation assays in Cos-1 cells transiently co-transfected with V5-and Myctagged proteins (Fig. 3a,b) . The experiments demonstrated that these proteins do not heterodimerize, ruling out the possibility of a dominant negative effect by SHOC2 S2G . Next, we explored whether SHOC2 S2G altered signaling through MAPK by expressing SHOC2 wt or SHOC2 S2G in Cos-1, 293T and Neuro2A cells. Although we did not observe significant change in ERK activation in Cos-1 and 293T cells (data not shown), SHOC2 S2G expression promoted enhanced EGFdependent ERK phosphorylation compared to wild-type SHOC2 in neuroblastoma Neuro2A cells (Fig. 3c,d) .
To further explore the functional effects of the SHOC2 S2G mutant, we used C. elegans as an experimental model. In C. elegans, reduced SUR-8 function (sur-8 rf ) causes no identifiable phenotype by itself but can suppress the gain-of-function LET-60 (let-60 gof )-induced multivulva phenotype (Muv) 4 . We tested whether expression of SHOC2 proteins could rescue the suppressed Muv phenotype in the sur-8 rf , let-60 gof genetic background (Supplementary Table 3 ). Although SHOC2 wt was able to replace SUR-8 functionally, SHOC2 S2G failed to do so. Expression of the mutant in let-60 gof worms did not suppress the Muv phenotype (Supplementary Table 3 ), excluding dominant negative effects for SHOC2 S2G . In worms with a wild-type genetic background, SHOC2 S2G expression at embryonic and early larval stages of development caused no visible phenotype. In contrast, at the early L3 stage, it caused abnormal vulval development, resulting in protruding vulva (Pvl), decreased egg laying efficiency (Egl) and accumulation of larvae inside the mother with the formation of bag-of-worms adults (Bag phenotype) (Supplementary Table 4 and Fig. 4 ). These neomorphic phenotypes were absent in animals expressing SHOC2 wt but were observed when SHOC2 wt tagged with an N-myristoylation sequence (myrHSHOC2 wt ) was expressed (Supplementary Table 4 and Fig. 4) . The SHOC2 S2G and myrH SHOC2 wt proteins were targeted to the cell membrane in various C. elegans cell types, whereas SHOC2 wt was observed diffusely throughout the cytoplasm and nucleus ( Fig. 4e-j) . The defects in vulva formation were not due to increased induction of the vulva cell fate in vulval precursor cells (VPC), as expression of SHOC2 S2G did not reduce the penetrance of the vulvaless phenotype of a let-23 rf hypomorph mutant (Supplementary Table 5 ), nor did it increase the penetrance of the Muv phenotype of let-60 gf animals (Supplementary Table 3 ). At the late L3 to early L4 stage, vulva morphogenesis normally begins with the descendants of VPC P6.p detaching from the cuticle and forming a symmetric invagination. Animals in which the expression of SHOC2 wt had been induced at early L3 maintained this pattern. In contrast, in larvae expressing SHOC2 S2G (17/48) or myrHSHOC2 wt (10/22) , descendants of VPCs P5.p and/or P7.p also detached from the cuticle, resulting in larger and more asymmetric invaginations ( Fig. 4k-n ). This morphogenesis defect was the earliest detectable neomorphic effect of the SHOC2 S2G mutation on vulval development. We discovered that a SHOC2 mutation promoting N-myristoylation of its protein product causes Noonan-like syndrome with loose anagen hair. This acquired fatty acid modification is unique in inherited human disease and results in constitutive membrane targeting that leads to increased MAPK activation in a cell context-specific manner. Cell-specific activation of the RAS pathway has also been observed in Noonan syndrome-associated SHP-2 mutants 12-14 . Although not well understood, this phenomenon explains why, despite the ubiquitousness of RAS signaling, development is perturbed in certain tissues in these disorders. It has recently been reported that SHOC2 functions as a regulatory subunit of the catalytic subunit of protein phosphatase 1 (PP1C) 6 . By binding GTP-MRAS, SHOC2 promotes PP1C translocation to the membrane, allowing PP1C-mediated RAF1 dephosphorylation at residue Ser259, which is required for stable RAF1 translocation to the plasma membrane and catalytic activation. Of note, the portion of RAF1 encoding Ser259 and adjacent residues, which represent a 14-3-3 protein binding site with inhibitory function, is a major hot spot for Noonan syndrome-causing mutations affecting RAF1 (ref. 9) . According to this model, constitutive membrane translocation of In excretory canal cells (e-g) and intestinal cells (h-j), SHOC2 wt protein is present throughout the cytoplasm (e,h), whereas both SHOC2 S2G (f,i) and myrHSHOC2 wt (g,j) are enriched in or restricted to the plasma membrane. Anti-V5 (red) was used to visualize SHOC2 proteins. In intestinal cells, nuclei express GFP due to pelt-2HGFP plasmid used as a marker for transformation. (k-n) Nomarski images of vulval precursor cells at the L3 stage. In animals expressing SHOC2 wt only P6.p descendants invaginate (k), whereas in SHOC2 S2G -(l,m) and myrHSHOC2 wt -expressing (n) animals, P5.p (l-n) and P7.p descendants (m,n) also detach from the cuticle. Black arrowheads point to P6.p descendant invagination, whereas white arrowheads point to P5.p and P7.p descendant invagination. Anterior is to the left and dorsal is up in all images. the disease-causing SHOC2 S2G is expected to promote prolonged PP1C-mediated RAF1 dephosphorylation at Ser259 and, consequently, sustained RAF1-stimulated MAPK activation, which is consistent with our findings. In C. elegans, N-myristoylated SHOC2 expression altered morphogenesis during vulval development, a process for which the involvement of Ras signaling is well established. Specification of VPCs, however, was not altered. Rather, perturbation of the morphogenetic movements of the VPC descendant cells was observed. Although numerous mutations that alter vulval specification and morphogenesis have been identified, far less is known about processes affecting only morphogenesis 15, 16 . It is possible that SHOC2 S2G alters RAS signaling in steps downstream of the induction of the vulval fate. Alternatively, SHOC2 S2G -induced vulva defects might arise through perturbation of signaling pathways other than RAS-MAPK, such as signaling mediated by the Rho GTPase, Rac, which are critical for vulval morphogenesis 17 .
A unique feature of the SHOC2 mutation is its association with loose anagen hair (LAH). This phenotype occurs in isolation or with Noonan syndrome and has been without molecular cause. Hair shafts from affected individuals show features of the anagen stage of hair follicle development, during which epithelial stem cells proliferate in the hair bulb 18 . In individuals with LAH however, hair bulbs lack internal and external root sheaths. Our findings suggest perturbation in the proliferation, survival or differentiation of epithelial stem cell-derived cells residing in hair follicles and implicate SHOC2-mediated signal transduction in this aspect of stem cell biology.
Finally, we successfully used the human interactome and a network-based statistical method to predict the involvement of a gene in human disease. Our leading candidate, SHOC2, was a relatively obscure gene that caused no distinctive phenotype when mutated in worms, providing evidence of the strength of this approach. In future projects, it is anticipated that successful candidates will not be deemed this favorable, necessitating resequencing of many low-probability candidate genes. Emerging interactome datasets and improved analytic methods are likely to enhance the predictive power of systems biology.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Accession Codes. GenBank: SHOC2, NM_007373.3; SHOC2, NP_031399.2. Ensembl: SHOC2, ENSG00000108061.
Note: Supplementary information is available on the Nature Genetics website.
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ONLINE METHODS
Constructing a mammalian protein-protein interaction network from available resources. The protein-protein and signaling networks we chose were all literature-based 'legacy' direct biochemical mammalian interactions from low-throughput functional experiments that had been extracted manually (literature curated). We did not include interactions from high-throughput methods, orthologous interactions from lower organisms or interactions predicted using in silico methods. We considered only direct biophysical binding or enzymatic interactions and excluded interactions based on functional association. The following available protein-protein interaction datasets were used: DIP 19 25 September 2006) . We choose these datasets because components in those networks were annotated with accession codes that permit data consolidation and those datasets were provided freely for analysis and reuse. All interactions from these databases are claimed to be direct biochemical interactions determined experimentally, and all include the PubMed reference for the research article that described the experiments used to identify the interactions. Consolidating interactions from the different network databases was accomplished by combining human, mouse and rat gene symbols using the xml version of Swiss Prot (21 June 2006).
Algorithm used to generate a list of Noonan syndrome candidate genes.
We began by considering the following problem: given a graph G in which a small subset of vertices S, SCG, are identified as seed nodes, in this case known disease genes that cause Noonan syndrome, find a close to minimum connected subgraph G¢ that includes the seed nodes in S while pruning out intermediate nodes and links that are not statistically significant for interacting with the seed list. In order to consider this problem, we used an algorithm with six instructional steps. (i) Combine available mammalian protein-protein interaction networks using as described 10 . (ii) Filter the merged network to prune out interactions from publications reporting high-throughput interaction data as described 10 (vi) Rank intermediates base on their links in background network versus links in subnetwork using a binomial proportions test as described 10 .
Subjects and mutation analysis. Genomic DNAs from a cohort of 96 subjects with Noonan syndrome or a phenotype suggestive of this disorder without mutation in previously identified disease genes (PTPN11, SOS1, KRAS, HRAS, RAF1, BRAF, MEK1 and MEK2) were screened for the entire SHOC2 coding region using high-throughput resequencing as previously described 26 . All sequence variants identified were verified by manual inspection of the chromatograms and putative causative mutations were verified using another independent sequencing reaction. SHOC2 was then analyzed in a panel of 410 mutationnegative individuals with Noonan syndrome or a clinically related phenotype by denaturing high-performance liquid chromatography and direct sequencing 26 . In this cohort, clinical features for the majority of subjects satisfied standardized diagnostic criteria [27] [28] [29] [30] [31] , but a few individuals who lacked sufficient features for a definitive diagnosis were also included. DNA from skin fibroblasts, hair bulbs and/or epithelial cells from the oral mucosa was extracted using standard protocols. Samples were collected under research projects approved by the Institutional Review Boards at the Istituto Superiore di Sanità, Mount Sinai School of Medicine, IRCCS-Casa Sollievo della Sofferenza, Università di Bologna, Ospedale 'Bambino Gesù' , Università di Torino, University of ErlangenNuremberg and Universitatsklinikum Hamburg-Eppendorf, with informed consent. Permission was obtained to publish the photographs of subjects shown in Figure 1 . When available, parental DNAs were sequenced to establish whether identified changes were de novo. Paternity was confirmed using the AmpF/STR Identifier PCR Amplification Kit (Applied Biosystems).
Functional analyses. In silico analysis of protein N-myristoylation was performed using the Myristoylator, TermiNator and NMT softwares available online. The nucleotide substitutions of interest were introduced in V5-and Myc-tagged (C terminus) human SHOC2 cDNA expression constructs by sitedirected mutagenesis (QuikChange Site-Directed Mutagenesis Kit, Stratagene). Cos-1, 293-T and Neuro2A cells were maintained in DMEM (Gibco) supplemented with 10% heat-inactivated FBS (Euroclone) and antibiotics and were transfected at 60-70% confluency using Fugene6 (Roche) or Lipofectamine 2000 (Invitrogen). N-myristoylation was evaluated by [ 3 H]myristic acid (30 mCi/ml) incorporation as described elsewhere 32 . Proteins immunoprecipitated with an anti-V5 antibody from cell lysates were separated by SDS-PAGE. Gels were fixed, soaked in Amplify (Perkin Elmer) for 30 min, dried under a GelAir drying frame (Bio-Rad) and exposed to X-ray film (Kodak) for 2 months. Cellular fractionation and ERK phosphorylation assays were performed on Cos-1 cells transiently expressing the V5-tagged SHOC2 wt or SHOC2 S2G using standard protocols 26, 33 . Cells were serum starved for 16 h and then stimulated with EGF (30-100 ng/ml) for the indicated intervals. In all experiments, a human NMT1 cDNA expression construct (Origene) was co-transfected to ensure that the amount of endogenous NMT would not be limiting.
Confocal laser scanning microscopy. 3 Â 10 3 cells were seeded on glass coverslips, transiently transfected, serum starved for 16 h and stimulated with EGF (30 ng/ml, 15 min). Cells were fixed with 3% paraformaldehyde (30 min, 4 1C), permeabilized with 0.5% Triton X-100 (10 min, 25 1C), and stained as described in the figure legends. Imaging was performed on a Leica TCS SP2 AOBS apparatus, using excitation spectral laser lines at 405, 488 and 594 nm, tuned with an acoustooptical tunable filter. Image acquisition and processing were conducted by using the Leica Confocal Software (Leica Lasertechnik GmbH). Signals from different fluorescent probes were taken in sequential scanning mode.
Generation of C. elegans strains and phenotypic analysis. Culture, maintenance and genetic crosses for nematodes were as described 34 . Nematode strains were provided by the Caenorhabditis Genetics Center (University of Minnesota). The following mutant alleles were used: sur-8 rf : sur-8(ku167) IV; let-60 gof : let-60(n1046) IV; let-23 rf : let-23(sy1) II. V5-tagged SHOC2 wt and SHOC2 S2G cDNA were subcloned into the heat shock-inducible pPD49.83 vector (a gift of A. Fire, Stanford University School of Medicine). A chimeric SHOC2 protein, myrHSHOC2 wt , in which the first seven amino acid residues were substituted by the N-terminal myristoylation signal (MGSCIGK) of src-2 was obtained via PCR amplification and cloned into the pPD49.83 vector. Germline transformation was performed as described 35 . elt-2HGFP (pJM67, a gift from J.D. McGhee, University of Calgary), which drives GFP expression in intestinal cells, was used as co-injection marker. At least three independent lines for each construct were tested for the Pvl phenotype after heat shock. All the lines expressing SHOC2 S2G or myrHSHOC2 wt upon heat shock showed a Pvl phenotype. Only the lines carrying the following transgenes were scored quantitatively at the compound microscope and used for further analyses and crosses: gbEx240[hsp16.2HSHOC2 wt HV5; pelt-2HGFP], gbEx208a[hsp16.2 HSHOC2 S2G HV5; pelt-2HGFP] and gbEx209[hsp16.2HmyrHSHOC2 wt HV5; pelt-2HGFP]. Genetic crosses were performed according to standard methods. The presence of sur-8(ku167), let-60(n1046) and let-23(sy1) alleles was confirmed by sequencing the appropriate region of genomic DNA from each transgenic strain. After each cross, isogenic worms that had lost the transgene were cloned separately and used as controls. Animals were scored blindly at the dissecting microscope to count the number of eggs in utero after cutting the mother (Egl), to identify animals that had become bags of worms (Bag) and to check for the presence of multiple ectopic pseudovulvae (Muv). A subset of worms was also scored blindly at the compound microscope for vulva morphology and VPC induction phenotypes.
C. elegans heat shock experiments, microscopy and immunocytochemistry. At different developmental stages, worms carrying the transgenes were subjected to heat shock at 33 1C for 30 min and then kept at 30 1C for 1 h. Synchronized embryos were heat shocked to study the effects of transgene expression on embryonic and early larval development, while synchronized L1 and L2 larvae were heat shocked to study the effects on later larval development, movement and fertility. To study VPC induction and vulva morphogenesis, hermaphrodites were heat shocked at early L3 stages and animals were scored for vulval induction at the L4 stage and for Pvl phenotype at the adult stage. Microscopy observations were performed with a Zeiss Axioskop equipped with epifluorescence and differential interference contrast on live animals anesthetized and mounted on 2% agarose pads containing 10 mM sodium azide. Images were collected with an Axiocam digital camera. Confocal analyses were performed using a Leica TCS SP2 microscope. For immunocytochemistry analyses, transgenic worms were heat shocked for 2 h and then were fixed with 2% PFA (25 1C, 5 min, 1 h on ice). They were processed as reported 36 and then incubated overnight in a dilution of anti-V5 monoclonal (1:200). After repeated washing for 24 h, animals were incubated overnight with secondary Texas Red-conjugated anti-mouse (1:100) (Invitrogen), washed and mounted for observation on microscope slides.
URLs. DIP, http://dip.doe-mbi.ucla.edu/; IntAct, ftp://ftp.ebi.ac.uk/pub/ databases/intact/current; MINT, http://mint.bio.uniroma2.it/mint/; Iyengar web resources, http://www.mssm.edu/labs/iyengar/resources; BIND, http:// www.bind.ca/; PDZBase, http://icb.med.cornell.edu/services/pdz/start; Prosite, http://www.expasy.ch/tools/scanprosite/; Pfam database, http://pfam.janelia. org/; Myristoylator, http://www.expasy.org/tools/myristoylator/; TermiNator, http://www.isv.cnrs-gif.fr/terminator3/index.html; NMT, http://mendel.imp. ac.at/myristate/SUPLpredictor.htm.
Noonan syndrome, a developmental disorder characterized by congenital heart defects, reduced growth, facial dysmorphism and variable cognitive deficits, is caused by constitutional dysregulation of the RAS-MAPK signaling pathway. Here we report that germline NRAS mutations conferring enhanced stimulus-dependent MAPK activation account for some cases of this disorder. These findings provide evidence for an obligate dependency on proper NRAS function in human development and growth.
The KRAS, NRAS and HRAS genes encode highly conserved small GTPases that act as membrane-associated molecular switches controlling intracellular signal flow by cycling between active, GTP-bound states and inactive, GDP-bound states 1 . Following the transmission of signals elicited by cell surface receptors, RAS proteins are activated by guanine nucleotide exchange factors. In the GTP-bound state, two regions, switch I and switch II, undergo a conformational change that enables RAS proteins to bind to and activate effector proteins, including RAF and phosphatidylinositol-3-kinases 2 . This interaction is terminated by hydrolysis of GTP to GDP, which promotes a switch toward the inactive RAS conformation. The low intrinsic GTPase activity of RAS proteins is enhanced by GTPase activating proteins (GAPs) 3 . Because of its nodal role in signal transduction, RAS function is required for many cellular processes, and its upregulation has been causally linked to oncogenesis and developmental disorders 2, 4 . These developmental disorders comprise a group of clinically related conditions characterized by facial dysmorphism, congenital cardiac defects, reduced growth and variable cognitive impairment and tumor predisposition. In these disorders, RAS signaling dysregulation is caused by germline mutations in HRAS or KRAS as well as in genes encoding modulators of RAS function (PTPN11, SOS1, SHOC2, NF1 and SPRED1) or downstream signal transducers (RAF1, BRAF, MEK1 and MEK2) [4] [5] [6] [7] . The common biological consequence of mutations associated with this group of diseases is altered, usually increased, signal traffic through the MAPK cascade.
Based on the evidence that Noonan syndrome (MIM163950) and the clinically related cardio-facio-cutaneous syndrome (MIM115150) are genetically heterogeneous, with mutations in known disease genes accounting for 70-80% of cases of each 6, 7 , a systematic scanning of the NRAS gene was performed on a cohort of 917 individuals negative for previously known mutations with a phenotype fitting or suggestive of these disorders (Supplementary Methods). We identified four unrelated individuals in this cohort heterozygous for the nucleotide changes C149T or G179A (resulting in the amino acid substitutions T50I and G60E, respectively) ( Fig. 1 and Supplementary Fig. 1 ). Three were sporadic cases, and parental DNA genotyping demonstrated the de novo origin of the mutations. The defects were documented in hair bulbs, urine exfoliated cells and/or buccal epithelial cell specimens, thus excluding a somatic event restricted to blood cells as the cause of the mutations (Supplementary Fig. 1 and data not shown). In the family transmitting the trait, the mutation segregated with disease. All NRAS mutation-positive subjects showed typical clinical features of Noonan syndrome (Supplementary Table 1 and Supplementary Fig. 2 ). b r i e f c o m m u n i c a t i o n s Both NRAS mutations affected amino acid residues highly conserved among RAS orthologs and paralogs (Fig. 1c and data not  shown) . Gly60 is located in the switch II region. A germline KRAS mutation affecting Gly60 (G60R) had previously been reported in cardio-facio-cutaneous syndrome 8 , and the somatic NRAS mutation G60E rarely occurs in malignancies (COSMIC database; see URLs below). Alterations of the neighboring Gln61 are frequent among oncogenic RAS alterations and are known to confer impaired GTPase function. In contrast, no somatic or germline RAS gene mutation affecting Thr50 has been described so far. Thr50 is an exposed residue located in the β2-β3 loop connecting the two switch regions (Fig. 1b) but is not predicted to be directly involved in GTP and GDP binding, GTP hydrolysis, or effector interaction (Supplementary Fig. 3) .
To elucidate the consequences of the Noonan syndrome-causing NRAS mutations on protein function and intracellular signaling, we expressed each mutant as yellow fluorescent protein-NRAS fusion proteins in cells from the COS-7 line, and their functional properties in vitro were compared with wild-type NRAS and the oncogenic NRAS substitution G12V, where the latter is known to be GAP resistant and to promote constitutive activation of MAPK signaling. Expression of the NRAS substitutions T50I or G60E resulted in enhanced phosphorylation of MEK and ERK in the presence of serum or after epidermal growth factor (EGF) stimulation but, in contrast with the G12V NRAS substitution, had only marginal effects on signaling in starved cells (Fig. 2a-c) . Of note, the G60E NRAS mutant, much like G12V, accumulated constitutively in the active, GTP-bound form and appeared resistant to GAP stimulation. In contrast, the T50I NRAS mutant was not enriched in the GTP-bound state (Fig. 2d,e) , indicating a different mechanism of functional dysregulation. Biochemical characterization of this alteration provided evidence that the T50I substitution does not substantially affect intrinsic GTPase activity, GAP association or GAP-stimulated hydrolysis. Similarly, no change was observed in guanine nucleotide exchange factor-catalyzed nucleotide release, effector association or allosteric activation of SOS1 (Supplementary Fig. 4) .
To explore further the structural and functional consequences of the T50I change, we determined the crystal structure of the RAS mutant bound to Gpp(NH)p (an analog of GTP), but no substantial structural rearrangements were observed (Supplementary Table 2 and Supplementary Fig. 5 ). Molecular dynamics simulations of wild-type RAS indicated that Thr50 directly interacts with the polar heads of membrane phospholipids and is an integral part of a recently described functional region that controls RAS membrane orientation and signal output (Supplementary Fig. 6 ) 9 . According to this model, aside from the conformational changes involving the switch I and II regions, GTP loading of membrane-anchored RAS is predicted to rearrange a distinct region of the GTPase (comprising the β2-β3 loop and helix α5) (Fig. 1c,d) . This, in turn, would lead to a differential engagement of the C-terminal hypervariable region and helix α4 with the membrane, ultimately altering the orientation of the entire G domain of RAS with respect to the membrane. Residues Asp47 and Glu49 have been shown to be directly involved in b r i e f c o m m u n i c a t i o n s the intermolecular binding network controlling RAS membrane orientation, and their substitution was found to enhance downstream signaling through GTP-bound RAS, presumably by keeping the GTPase in a more signaling-competent orientation 9 . Consistent with this model, the RASbinding domain of RAF1 is able to recognize the relative membrane orientation of GTP-bound RAS, which is functionally translated into different signaling outputs 9 . Based on this model, we hypothesize that the T50I substitution might alter RAS orientation in a fashion similar to that documented for the D47A and E49A substitutions 9 ( Supplementary  Fig. 6 ), bolstering the interaction of GTP-bound RAS with its effectors. This proposed mechanism would explain the enhanced signal flow through the MAPK cascade in the absence of any substantial accumulation of the T50I NRAS substitution in its GTP-bound form (Fig. 2) . Taken together, these findings support the idea that Noonan syndrome-causing NRAS mutants are weak hypermorphs. Although the G60E NRAS substitution accumulates in its GTP-bound form to mimic the consequences of oncogenic substitutions affecting Gly12 or Gly13, the weakened effector binding of this mutant might account for its damped downstream effect compared to the oncogenic G12V alteration.
Here we reported that Noonan syndrome can be caused by altered signaling through NRAS. Similar to what has been observed for germline KRAS mutations causing Noonan syndrome and cardiofacio-cutaneous syndrome, germline NRAS alterations do not affect residues commonly mutated in human cancers and appear to be less activating in dysregulating intracellular signaling in vitro compared with cancer-associated somatic mutations. Considering the large size of the cohorts of affected individuals included in this study, germline NRAS mutations are estimated to be substantially less frequent than those affecting KRAS or HRAS 7 . Although we favor the hypothesis that NRAS mutations rarely occur as germline defects because of their severe consequences on embryonic and fetal development, we cannot exclude the possibility that mutations other than those described here may cause phenotypes not recognized as Noonan syndrome or related disorders. Notably, Oliveira and colleagues reported on an individual with a germline NRAS missense change (G13D) and an autoimmune lymphoproliferative disorder, without any signs of Noonan syndrome 10 . Although their observation has not been replicated so far, their findings could be consistent with the occurrence of non-overlapping allele-specific phenotypic effects resulting from different NRAS mutations than those described here.
The identification of activating NRAS mutations in Noonan syndrome provides evidence for an obligate dependency on proper function of this small GTPase in human development and growth. Even though functional redundancy among RAS proteins does exist, biological differences in these proteins are also well documented 11, 12 . Recent evidence gathered from mouse models demonstrated that these GTPases play distinct roles in development. Although loss of Kras isoforms is lethal at the embryonic stage, disruption of mouse Hras and Nras does not meaningfully perturb development. Consistently, it has been documented that RAS proteins generate distinct signal outputs despite their interaction with a shared set of activators and effectors 11, 12 , and preferential associations between specific human cancers and individual RAS genes have also been established (see COSMIC database). These and recent findings regarding Noonan syndrome and related disorders extend this concept to germline mutations and human development, showing that distinct clusters of activating mutations in the three RAS genes underlie a group of clinically related mendelian traits. Notably, whereas a small number of mutations in HRAS and NRAS underlie, respectively, Costello syndrome (MIM218040) and Noonan syndrome, a more diverse set of missense changes in KRAS results in a markedly broad phenotypic continuum 13 . Further studies are required to understand such genotype-phenotype correlations. The localization of RAS isoforms to distinct signaling nanoclusters and their ability to differentially activate canonical and non-canonical pathways, rather than distinct tissue-or cell-specific expression patterns, are believed to underlie the functional diversity of these GTPases 11, 12, 14 . Accordingly, phenotypic differences between Noonan, cardio-facio-cutaneous and Costello syndromes might be ascribed to different developmental consequences strictly depending upon these mechanisms, although the obvious similarities of these disorders testify that there are important functions in developmental programs that are shared by all members of this family of GTPases.
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